Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (May 2023)
32 slides from Dimerix's investor presentation, May 4, 2023
Slide 1: Capital Raising Presentation May 2023
ACTIONS FSGS CLINICAL STUDY @ Dimerix (ASX:DXB) Capital Raising Presentation May 2023 For personal use only Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be ma
Slide 3: Late stage, phase 3 clinical development asset
Late stage, phase 3 clinical development asset Orphan Drug status providing protection through data exclusivity? for min 7-10 years, in addition to comprehensive patent/IP strategy Near term Phase 3 interim analysis results announced (Q124) Estimated >3b global market negotiations with offers size p
Slide 4: Significantly de-risked, late-stage development program
Significantly de-risked, late-stage development program = Cc jo) ®o 12) =) _ Strong safety profile!— no Proven efficacy'in Phase 2 Ghnnicted Dicontt (40) material adverse events in studies — Met primary and studies?- expect no further Cc Phase 1/2 secondary endpoints work required by FDA je) i?) = 2
Slide 5: Development pipeline
Development pipeline Program Indication Core focus { Focal Segmental Glomerular Sclerosis (FSGS) DMX-200 Diabetic Kidney Disease DMX-700 Chronic Obstructive Pulmonary Disease (COPD) DMX-xxx Undisclosed (multiple) For personal use only @ Dimerix
Slide 6: For personal use only
For personal use only • • • • • • • • •
Slide 7: For personal use only
• • ▪ For personal use only ▪ ▪ • $14.00 $12.00 $10.00 Share Price $8.00 $6.00 $4.00 $2.00 $0.00 Neuren Pharmaceuticals Limited (ASX:NEU) - Share Pricing
Slide 8: For personal use only
For personal use only • • • • • • • ▪ ▪ ▪ ▪ ▪ ▪ ▪
Slide 9: FSGS market size
FSGS market size For personal use only FSGS 7MM market > Assuming US$9,900k/month as size estimated to be example pricing in the US (same pricing as Sparsentan in IgAN)? U S 3 Dp.at > Current market specifically for FSGS does not exist FSGS Market Size Region Estimated diagnosed patients iS p.a g (2
Slide 10: For personal use only
For personal use only • • • ▪ • • • •
Slide 11: Significant new partnering interest
Significant new partnering interest * Dimerix has received a significant amount of partnering interest from global pharma companies since starting its Phase 3 trial = Received multiple non-binding term sheets for global deals and regional deals! = With multiple parties in data room and conducting du
Slide 12: Phase 3 clinical trial
PHASE 3 CLINICAL TRIAL ACTIGNS FSGS CLINICAL STUDY For personal use only @ Dimerix
Slide 13: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease For personal use only AT1R — blocked by angiotensin receptor blocker (ARB) CCR2-—CCR2 is the receptor for aa MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys? Hyperfiltration of and hypertension within blood
Slide 14: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) only fo) 12) =) © New Chemical Entity status, 2 x 120mg capsule daily Consistently safe and well 4 clinical studies com
Slide 15: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints : Average reduction in proteinuria after 16 weeks Clinically meaningful outcomes for patients treatment on DMX-200 versus placebo compared to standard of care alone in FSGS patients! For personal use only 0.0% 8 3 -5.0% fee & le 8 ps as = 2s 2s &
Slide 16: uMCR normalised to baseline v time
For personal use only uMCR normalised to baseline v time N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -50% 0.5 On placebo On active 0.0 0 5 10 15 Time (weeks) • ▪ ▪
Slide 17: Phase 3 Clinical trial status
O ACTICN Phase 3 Clinical trial status FSGS CLINICAL STUDY global study recruiting across “70 sites in 11 countries: * Geographically diverse to meet differing regulatory requirements; ~ rv) Part 1: randomised, double-blind, multi-centre, lacebo-controlled study of renal putcomes of DMX-200 in patie
Slide 18: Part 1 interim analysis Q1 2024
Oo ACTING Part 1 interim analysis Q1 2024 FSGS CLINICAL STUDY Announcement of interim analysis of Phase 3 trial expected in early 2024 A successful outcome would see the Company announce a Clinically significant and statistical meaningful improvement in proteinuria vs placebo and the trial is contin
Slide 19: Changes & additions to draft 2021 plan
Changes & additions to draft 2021 ACTIGNS plan FSGS CLINICAL STUDY Draft study protocol provided basis for budget, prior to regulatory submissions and study approval in Zaitferent countries: Draft protocol amended to broaden eligibility criteria and incorporate regulatory feedback + Part 1 study pro
Slide 20: Late stage, phase 3 clinical development asset
Late stage, phase 3 clinical development asset Orphan Drug status providing protection through data exclusivity? for min 7-10 years, in addition to comprehensive patent/IP strategy Near term Phase 3 interim analysis results announced (Q124) Estimated >3b global market negotiations with offers size p
Slide 21: Offer Summary
@ Dimerix OFFER SUMMARY
Slide 22: For personal use only
For personal use only • • • • • • • • o o
Slide 23: Use of funds
Use of funds + Capital raising of up to A$12 million will fund the company through to Q1 2024, past the expected announcement of Phase 3 interim analysis + A$16.0m! pro forma cash balance post capital raising D> + A$36.2m? pro forma cash balance post capital raising and including option exercise 7 +
Slide 24: Convertible Note overview
Convertible Note overview” Dimerix has secured up to $12.0m of funding through a convertible note agreement with an initial tranche of $3.5m and a further optional tranche of up to $8.5m y eonl ‘onvertible Note Overview inversion Price nal use mmencement Shares ios yOptions je) Lkedemption aysg Conv
Slide 25: Offer timetable
Offer timetable* For personal use only Trading halt Announcement of Capital Raise and recommencement of trading Record date for Entitlement Offer Entitlement Offer opening date Entitlement Offer closing date (5:00pm, Sydney time) Issue date of securities under the Entitlement Offer Monday, 1 May 202
Slide 26: For personal use only
For personal use only • • • • • • • • • •
Slide 27: International Offer restrictions
International Offer restrictions This document does not constitute an offer of new ordinary shares and free-attaching options (“New Securities") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Securities
Slide 28: For personal use only
For personal use only
Slide 29: Advancing the broader pipeline
Advancing the broader pipeline Additional longer term pipeline opportunities diversify risk and potential sources of revenue DMX-700 for Chronic DMX-200 for Diabetic Undisclosed Opportunities Obstructive Pulmonary Kidney Disease Disease (COPD) Preclinical studies show that DMX-700 Phase 2 demonstrat
Slide 30: Corporate overview
Corporate overview SHARE PRICE issue For personal use only QBAsx Ticker Symbol ASX:DXB ae ¥ ae Cash Balance (Mar23) “A$4.0 million Wi id ead ae gS = eee eS SS Se ee 9, Market Capitalisation “A$30 million — au tal ale seceded dl A. ail a. tad da |~ Share price “A$O10 ZS Total ordinary shares on 320,8
Slide 31: For personal use only
For personal use only Nina Webster Hugh Alsop Sonia Poli Clinton Snow PhD, MBA, M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Wyeth (Pfizer), Acrux, Immuron Mayne Pharma, Acrux, Hatchtech, Hoffman la Roche,
Slide 32: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 42